A carregar...
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
The BCR-ABL kinase inhibitor imatinib mesylate is currently the standard therapy for patients with chronic myeloid leukemia (CML). Despite the remarkable results achieved with imatinib for the treatment of CML, the emergence of resistance to this drug has become a significant problem. Mutations with...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2994207/ https://ncbi.nlm.nih.gov/pubmed/21127752 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|